Association of Paraoxonase 1 Gene Polymorphism and Enzyme Activity with Carotid Plaque in Rheumatoid Arthritis

Overview

Journal Arthritis Rheum

Specialty Rheumatology

Date 2013 Aug 7

PMID 23917967

Citations 27

Authors

Christina Charles-Schoeman

Yuen Yin Lee

Ani Shahbazian

Alan H Gorn

John FitzGerald

Veena K Ranganath

Mihaela Taylor

Nagesh Ragavendra

Maureen McMahon

David Elashoff

Srinivasa T Reddy

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the relationship of genetic and biochemical determinants of paraoxonase 1 activity to carotid plaque as a surrogate marker of cardiovascular (CV) risk in patients with rheumatoid arthritis (RA).

Methods: The relationships between paraoxonase 1 activity, PON1 genotype (for the functional polymorphism at position 192), and carotid plaque presence were determined in 168 RA patients. After an overnight fast, blood was collected for lipoprotein analysis, and paraoxonase 1 activity was measured using paraoxon as the substrate. The PON1 Q192R genotype was determined for all patients. Lipoprotein cholesterol levels, traditional CV risk factors, medication use, and RA disease characteristics were assessed for all patients.

Results: Paraoxonase 1 activity values in the RA patients were highest for the RR genotype, intermediate for the QR genotype, and lowest for the QQ genotype (P < 0.0001). Compared to patients with either the QQ genotype or the QR genotype, patients with the RR genotype demonstrated decreased risk of carotid plaque on multivariate analysis, controlling for traditional CV risk factors, high-sensitivity C-reactive protein levels, prednisone use, and cholesterol-lowering medication use (P < 0.05). Additional multivariate logistic regression analysis controlling for the above factors also revealed a significant association of plasma paraoxonase 1 activity with carotid plaque in RA patients. Lower plasma paraoxonase 1 activity was associated with increased risk of carotid plaque (P < 0.05).

Conclusion: The current findings suggest a relationship of the genetic determinants and activity of paraoxonase 1 to CV risk in RA patients, as assessed by the presence or absence of carotid plaque. Further CV outcome studies are warranted to validate the utility of paraoxonase 1 as a biomarker of CV risk in patients with RA.

Citing Articles

Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins.

Razmjou A, Kremer J, Pappas D, Curtis J, Wang J, Shahbazian A RMD Open. 2024; 10(4).

PMID: 39461874 PMC: 11529732. DOI: 10.1136/rmdopen-2024-004829.

Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis.

Charles-Schoeman C, Wang J, Shahbazian A, Wilhalme H, Brook J, Kaeley G Rheumatol Int. 2023; 43(6):1041-1053.

PMID: 36828925 PMC: 10125943. DOI: 10.1007/s00296-023-05285-7.

Suppressed paraoxonase-1 activity associates with elevated oxylipins and the presence of small airways disease in patients with rheumatoid arthritis.

Razmjou A, Wang J, Shahbazian A, Reddy S, Charles-Schoeman C Clin Rheumatol. 2022; 42(1):75-82.

PMID: 36138190 PMC: 9823017. DOI: 10.1007/s10067-022-06375-w.

Osteoprotegerin and MTHFR gene variations in rheumatoid arthritis: association with disease susceptibility and markers of subclinical atherosclerosis.

Arida A, Nezos A, Papadaki I, Sfikakis P, Mavragani C Sci Rep. 2022; 12(1):9534.

PMID: 35680906 PMC: 9184606. DOI: 10.1038/s41598-022-13265-3.

Identification of hub genes and transcription factors in patients with rheumatoid arthritis complicated with atherosclerosis.

Xiao L, Yang Z, Lin S Sci Rep. 2022; 12(1):4677.

PMID: 35304503 PMC: 8933589. DOI: 10.1038/s41598-022-08274-1.

References

Tanimoto N, Kumon Y, Suehiro T, Ohkubo S, Ikeda Y, Nishiya K . Serum paraoxonase activity decreases in rheumatoid arthritis. Life Sci. 2003; 72(25):2877-85. DOI: 10.1016/s0024-3205(03)00195-4. View

Fries J, Spitz P, Kraines R, HOLMAN H . Measurement of patient outcome in arthritis. Arthritis Rheum. 1980; 23(2):137-45. DOI: 10.1002/art.1780230202. View

Schwartz G, Olsson A, Abt M, Ballantyne C, Barter P, Brumm J . Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 367(22):2089-99. DOI: 10.1056/NEJMoa1206797. View

Evans M, Escalante A, Battafarano D, Freeman G, OLeary D, del Rincon I . Carotid atherosclerosis predicts incident acute coronary syndromes in rheumatoid arthritis. Arthritis Rheum. 2011; 63(5):1211-20. PMC: 3286362. DOI: 10.1002/art.30265. View

Charles-Schoeman C, Khanna D, Furst D, McMahon M, Reddy S, Fogelman A . Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol. 2007; 34(7):1459-64. View

del Rincon I, Williams K, Stern M, Freeman G, Escalante A . High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2002; 44(12):2737-45. DOI: 10.1002/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-%23. View

Bild D, Detrano R, Peterson D, Guerci A, Liu K, Shahar E . Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2005; 111(10):1313-20. DOI: 10.1161/01.CIR.0000157730.94423.4B. View

Costa L, Vitalone A, Cole T, Furlong C . Modulation of paraoxonase (PON1) activity. Biochem Pharmacol. 2005; 69(4):541-50. DOI: 10.1016/j.bcp.2004.08.027. View

Watson A, Navab M, Hama S, Sevanian A, Prescott S, Stafforini D . Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest. 1995; 95(2):774-82. PMC: 295551. DOI: 10.1172/JCI117726. View

10.

Costa L, Cole T, Jarvik G, Furlong C . Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med. 2003; 54:371-92. DOI: 10.1146/annurev.med.54.101601.152421. View

11.

Prevoo M, van t Hof M, Kuper H, van Leeuwen M, van de Putte L, van Riel P . Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995; 38(1):44-8. DOI: 10.1002/art.1780380107. View

12.

Solomon D, Karlson E, Rimm E, Cannuscio C, Mandl L, Manson J . Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003; 107(9):1303-7. DOI: 10.1161/01.cir.0000054612.26458.b2. View

13.

Aubry M, Maradit-Kremers H, Reinalda M, Crowson C, Edwards W, Gabriel S . Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol. 2007; 34(5):937-42. View

14.

Barter P, Caulfield M, Eriksson M, Grundy S, Kastelein J, Komajda M . Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007; 357(21):2109-22. DOI: 10.1056/NEJMoa0706628. View

15.

Navab M, Van Lenten B, Fonarow G, Cardinez C, Castellani L, Brennan M . Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997; 99(8):2005-19. PMC: 508026. DOI: 10.1172/JCI119369. View

16.

Navab M, Hama S, Anantharamaiah G, Hassan K, Hough G, Watson A . Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000; 41(9):1495-508. View

17.

Navab M, Hama S, Cooke C, Anantharamaiah G, Chaddha M, Jin L . Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000; 41(9):1481-94. View

18.

Fischer L, Schlienger R, Matter C, Jick H, Meier C . Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of first-time acute myocardial infarction. Am J Cardiol. 2004; 93(2):198-200. DOI: 10.1016/j.amjcard.2003.09.037. View

19.

Kerekes G, Szekanecz Z, Der H, Sandor Z, Lakos G, Muszbek L . Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of inflammation and autoimmunity. J Rheumatol. 2008; 35(3):398-406. View

20.

Durrington P, Mackness B, Mackness M . Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001; 21(4):473-80. DOI: 10.1161/01.atv.21.4.473. View